Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!

Chinese ADC Drug Targeting B7-H3 Approved for Clinical Trials!

ADC

#ADC #Immunotherapy#B7H3 #LungCancer #HeadAndNeckCancer #ADCDrug

On September 20, the China National Medical Products Administration (NMPA) approved BeiGene’s innovative anti-cancer drug, BGB-C354, for clinical trials. This exciting news marks the first approval for clinical research of this novel molecule in China. BGB-C354 is an Antibody-Drug Conjugate (ADC) specifically designed to target B7-H3, a protein often overexpressed in various cancers such as lung cancer, prostate cancer, breast cancer, and squamous cell carcinoma of the head and neck.

BGB-C354 holds significant promise for treating patients with advanced solid tumors, particularly lung cancer and head and neck squamous cell carcinoma (HNSCC). B7-H3 has gained attention as a key anti-cancer target, with its high expression often linked to poor prognosis. By leveraging the power of ADC technology, BGB-C354 aims to selectively deliver potent anti-cancer drugs directly to tumor cells, minimizing damage to healthy cells.

BeiGene has already initiated a Phase 1 clinical trial in the US and Australia, evaluating the safety, tolerability, and preliminary anti-tumor activity of BGB-C354 as a monotherapy and in combination with anti-PD-1 antibody, Tislelizumab. This recent approval sets the stage for the commencement of clinical trials in China.

Globally, B7-H3-targeted therapies are advancing rapidly. Companies like Daiichi Sankyo, Merck, and GSK are pushing the boundaries with their ADCs, entering Phase 2 and 3 clinical trials. The approval of BGB-C354 marks a significant step in advancing cancer treatment options in China, offering new hope for patients with difficult-to-treat cancers.

To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #ClinicalTrials #BeiGene #OncologyBreakthrough #PharmaInnovation #CancerResearch

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago Solid tumor

**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**

**Breakthrough Chinese Monoclonal ADC Targets Nectin-4: Achieving 91.9% Disease Control Rate Across Multiple Solid Tumors**

Monoclonal ADC

#MonoclonalADC #Nectin4 #Solidtumor #9MW2821 #cervicalcancer #urothelialcarcinoma #esophagealcancer #breastcancer

Meet 9MW2821, a groundbreaking monoclonal antibody-drug conjugate (ADC) developed in China that targets Nectin-4, an adhesion molecule highly expressed in several solid tumors, including cervical cancer (CC), urothelial carcinoma (UC), esophageal cancer (EC), and breast cancer. Recently, this innovative therapy was granted Breakthrough Therapy Designation by the China Center for Drug Evaluation (CDE) for treating locally advanced or metastatic urothelial carcinoma, specifically in patients who have previously failed platinum-based chemotherapy and PD-(L)1 inhibitors.

The latest clinical results were unveiled at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the remarkable efficacy of 9MW2821 in a Phase 1/2 trial involving 260 patients with various advanced solid tumors. These included UC, triple-negative breast cancer (TNBC), EC, and CC. Among 37 evaluable UC patients, the disease control rate (DCR) soared to an impressive 91.9%, with an objective response rate (ORR) of 62.2%. Additionally, the median overall survival (mOS) reached 14.2 months, while the median progression-free survival (mPFS) was 8.8 months.

This promising therapy is poised to redefine treatment paradigms for patients with advanced solid tumors who have limited options, marking a significant milestone in the global oncology landscape.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp:+8613717959070

（Https://wa.me/+8613717959070）

Email: doctor.huang@globecancer.com

#OncologyBreakthrough #CancerTreatment #Nectin4 #ADC #ClinicalResearch #Immunotherapy #UC #TNBC #CancerAwareness #BiotechInnovation